Get the Stockscreener App
2.18
0.00%
0.00
After Hours:
2.18
Cns Pharmaceuticals Inc stock is traded at $2.18, with a volume of 38,569.
It is up +0.00% in the last 24 hours and down -25.85% over the past month.
CNS Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. It is involved in the development of Berubicin, which is a therapy for the treatment of glioblastoma. Glioblastomas are tumors that arise from astrocytes, which are star-shaped cells that make up the supportive tissue of the brain.
See More
Previous Close:
$2.18
Open:
$2.34
24h Volume:
38,569
Relative Volume:
0.86
Market Cap:
$1.35M
Revenue:
-
Net Income/Loss:
$-15.85M
P/E Ratio:
-0.0912
EPS:
-23.9055
Net Cash Flow:
$-13.83M
1W Performance:
-4.19%
1M Performance:
-25.85%
6M Performance:
-79.38%
1Y Performance:
-82.36%
1-Day Range:
$2.10
$2.35
1-Week Range:
$2.10
$2.3503
52-Week Range:
$2.0573
$34.80
Cns Pharmaceuticals Inc Stock (CNSP) Company Profile
Name
Cns Pharmaceuticals Inc
Sector
Industry
Phone
1-800-946-9185
Address
2100 WEST LOOP SOUTH, HOUSTON
Compare CNSP vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CNSP
Cns Pharmaceuticals Inc
|
2.18 | 1.35M | 0 | -15.85M | -13.83M | -23.91 |
VRTX
Vertex Pharmaceuticals Inc
|
443.92 | 109.85B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
775.53 | 80.38B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
785.07 | 47.60B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
327.25 | 42.63B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
312.19 | 33.72B | 5.36B | 287.73M | 924.18M | 2.5229 |
Cns Pharmaceuticals Inc Stock (CNSP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-28-20 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Aug-24-20 | Initiated | Ladenburg Thalmann | Buy |
Cns Pharmaceuticals Inc Stock (CNSP) Latest News
Profit Recap: Why is CNS Pharmaceuticals Inc stock going down2026 Macro Impact & Smart Swing Trading Alerts - baoquankhu1.vn
Exit Recap: Is CNS Pharmaceuticals Inc in a long term uptrend2026 Valuation Update & Daily Stock Momentum Reports - baoquankhu1.vn
CNS Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
CNSP PE Ratio & Valuation, Is CNSP Overvalued - Intellectia AI
CNS Pharmaceuticals | 10-K: Annual report - Moomoo
CNS Pharmaceuticals 10-K: Net loss $15.85M, Loss per share $35.75 - TradingView
CNS Pharmaceuticals (NASDAQ: CNSP) pivots to neurology and oncology amid going concern risk - Stock Titan
Pharma News: Will CNS Pharmaceuticals Inc outperform small cap indexesDip Buying & Verified Short-Term Trading Plans - baoquankhu1.vn
CNS Pharmaceuticals Inc expected to post a loss of $5.09 a shareEarnings Preview - TradingView
CNS PHARMACEUTICALS INC (CNSP) Fundamental Analysis & Valuation - ChartMill
Lunai Bioworks, Inc. (LNAI) Stock: No-Reset Convertible Deal Boosts CNS Drug Development Edge - parameter.io
Lunai Bioworks Executes $20M Strategic Transaction at Fixed $1.50 Conversion, Acquiring BBB Delivery Platform for CNS Alzheimer's Therapies with Broad CNS Delivery Applications - PR Newswire
Is CNS Pharmaceuticals Inc in a long term uptrend2026 Earnings & Real-Time Market Sentiment Reports - baoquankhu1.vn
Stop Loss: Will CNS Pharmaceuticals Inc outperform small cap indexesPortfolio Performance Summary & Growth Oriented Trade Recommendations - baoquankhu1.vn
Aug Decliners: Is CNS Pharmaceuticals Inc forming a bullish divergence2026 Biggest Moves & Weekly Return Optimization Plans - baoquankhu1.vn
Movement Recap: Is CNS Pharmaceuticals Inc stock good for income investors2026 Movers & Low Risk High Win Rate Stock Picks - baoquankhu1.vn
CNSP SEC FilingsCNS Pharmaceuticals 10-K, 10-Q, 8-K Forms - Stock Titan
Death Cross: Is CNS Pharmaceuticals Inc forming a bullish divergence2026 Technical Overview & Free Community Consensus Stock Picks - baoquankhu1.vn
Will CNS Pharmaceuticals Inc stock go up in YEARWeekly Earnings Recap & Verified Swing Trading Watchlists - baoquankhu1.vn
CNS Pharmaceuticals shifts focus to neurology, oncology assets By Investing.com - Investing.com Nigeria
Quarterly Trades: Is CNS Pharmaceuticals Inc currently under institutional pressure2026 Trading Recap & Long-Term Capital Growth Strategies - baoquankhu1.vn
Acadia Pharmaceuticals to Participate in the Stifel 2026 Virtual CNS Forum - Business Wire
CNS Pharmaceuticals Unveils Strategic Pivot to Broader Oncology - The Globe and Mail
CNSP Implements New Strategy to Enhance Neurology and Oncology P - GuruFocus
CNS Pharmaceuticals Announces Strategic Shift to Neurology and Oncology Pipeline Expansion - citybuzz -
CNS Pharmaceuticals Launches Strategic Pivot Led by New Executive Team, Targeting High-Value Neurology and Oncology Assets for Investor Growth 123 - Minichart
CNS Pharmaceuticals (NASDAQ: CNSP) Launches New Growth Strategy Focused On Neurology and Oncology Pipeline Expansion - Digital Journal
CNS Pharma wipes glioblastoma pipeline clean in strategic pivot to fresh neurology, oncology targets - Fierce Biotech
CNS Pharmaceuticals shifts focus to neurology, oncology assets - Investing.com
CNS Pharmaceuticals launches strategic pivot, names new executive team and begins asset search - TradingView
CNS Pharmaceuticals Launches New Corporate Strategy Focused on Building a High-Value Neurology and Oncology Pipeline - ACCESS Newswire
New CNS Pharmaceuticals (NASDAQ: CNSP) team drives strategic pivot - Stock Titan
CNS Pharma shifts from single cancer focus to hunting new brain and tumor drugs - Stock Titan
Aug Final Week: Can CNS Pharmaceuticals Inc outperform under higher oil prices2026 Market Mood & Detailed Earnings Play Strategies - baoquankhu1.vn
CNS Drug Developers Add Pharma Veterans as Sector Nears First FDA Decisions - PR Newswire
CNS Pharmaceuticals (CNSP) Receives a Buy from Maxim Group - The Globe and Mail
Why is CNS Pharmaceuticals Inc stock going down2025 Price Momentum & Short-Term High Return Strategies - baoquankhu1.vn
CNSP Earnings History & Surprises | EPS & Revenue Results | CNS PHARMACEUTICALS INC (NASDAQ:CNSP) - ChartMill
9,500 RSUs awarded to CNS Pharmaceuticals (CNSP) CFO - Stock Titan
CNS Pharmaceuticals (CNSP) files insider Form 3 for Chief Financial Officer - Stock Titan
CNSP Financials: Income Statement, Balance Sheet & Cash Flow | CNS Pharmaceuticals - Stock Titan
CNS Pharmaceuticals Appoints New Chief Medical Officer - The Globe and Mail
CNS Pharmaceuticals (NASDAQ: CNSP) Appoints Lynne Kelley as Chief Medical Officer - The Globe and Mail
CNS Pharmaceuticals names Lynne Kelley as chief medical officer By Investing.com - Investing.com Australia
CNS Pharmaceuticals (NASDAQ: CNSP) appoints new CMO Lynne Kelley - Stock Titan
CNS Pharmaceuticals (NASDAQ: CNSP) Appoints New Executive Leadership Team - Digital Journal
CNS Pharmaceuticals appoints Lynne Kelley as CMO - TipRanks
CNS Pharmaceuticals names Lynne Kelley as chief medical officer - Investing.com
CNS Pharmaceuticals Appoints Lynne Kelley, MD, FACS, as Chief Medical Officer, Completing Executive Leadership Team - ACCESS Newswire
Brain cancer drug developer hires veteran surgeon to lead studies - Stock Titan
Supernus Pharmaceuticals Record Revenues And New CNS Drugs Prompt Valuation Questions - Sahm
Cns Pharmaceuticals Inc Stock (CNSP) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.51%
1.75%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):